Apellis Pharmaceuticals and Sobi reached a capped royalty purchase agreement following FDA approval of EMPAVELI.
5 reports, 2 independent
Updated Aug 13
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Apellis Pharmaceuticals and Sobi reached a capped royalty purchase agreement following FDA approval of EMPAVELI.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA approved EMPAVELI, leading to a capped royalty purchase agreement between Apellis and Sobi.1 source
Apellis stock price targets rise following FDA approval of Empaveli for kidney diseases.1 source
Keep exploring
The entities involved
-
Apellis Pharmaceuticals (United States)
company in Crestwood, United States
Nothing else this week.
-
sobi
German beverage store chain
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyFDA Approval and Strategic Deals Drive Apellis Pharmaceuticals’ Stock Higher for the Week Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the 11 Best Short-Term Stocks to Invest in. The company
- Insider MonkeyApellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target We recently published 10 Stocks Crushing With Whopping Double-Digit Gains. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the
- GlobeNewswireApellis Pharmaceuticals Reports Second Quarter 2025 Financial Results Received U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treatment of patients 12 years and older with C3G and primary IC-MPG
- Unknown outlet
- Unknown outlet